WO1992002623A1 - CLONING AND EXPRESSION OF A RHOPTRY ASSOCIATED PROTEIN OF $i(P.FALCIPARUM) - Google Patents
CLONING AND EXPRESSION OF A RHOPTRY ASSOCIATED PROTEIN OF $i(P.FALCIPARUM) Download PDFInfo
- Publication number
- WO1992002623A1 WO1992002623A1 PCT/AU1991/000338 AU9100338W WO9202623A1 WO 1992002623 A1 WO1992002623 A1 WO 1992002623A1 AU 9100338 W AU9100338 W AU 9100338W WO 9202623 A1 WO9202623 A1 WO 9202623A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rap
- kda
- protein
- recombinant dna
- recombinant
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 107
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 82
- 241000223960 Plasmodium falciparum Species 0.000 title claims abstract description 19
- 206010035500 Plasmodium falciparum infection Diseases 0.000 title abstract description 7
- 238000010367 cloning Methods 0.000 title description 13
- 239000012634 fragment Substances 0.000 claims abstract description 25
- 108020004511 Recombinant DNA Proteins 0.000 claims abstract description 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 15
- 229920001184 polypeptide Polymers 0.000 claims abstract description 14
- 230000000890 antigenic effect Effects 0.000 claims abstract description 7
- 239000013598 vector Substances 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 15
- 239000002773 nucleotide Substances 0.000 claims description 11
- 125000003729 nucleotide group Chemical group 0.000 claims description 11
- 102000053602 DNA Human genes 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 9
- 229960005486 vaccine Drugs 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- 239000013599 cloning vector Substances 0.000 claims description 5
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 235000018102 proteins Nutrition 0.000 description 78
- 108020004414 DNA Proteins 0.000 description 30
- 244000045947 parasite Species 0.000 description 18
- 102000001390 Fructose-Bisphosphate Aldolase Human genes 0.000 description 15
- 108010068561 Fructose-Bisphosphate Aldolase Proteins 0.000 description 15
- 150000001413 amino acids Chemical group 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 241000282693 Cercopithecidae Species 0.000 description 11
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 210000000349 chromosome Anatomy 0.000 description 9
- 238000012163 sequencing technique Methods 0.000 description 9
- 101001130441 Homo sapiens Ras-related protein Rap-2a Proteins 0.000 description 7
- 102100031420 Ras-related protein Rap-2a Human genes 0.000 description 7
- 108091005804 Peptidases Proteins 0.000 description 6
- 239000004365 Protease Substances 0.000 description 6
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 6
- 201000004792 malaria Diseases 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 101100173636 Rattus norvegicus Fhl2 gene Proteins 0.000 description 5
- 238000002105 Southern blotting Methods 0.000 description 5
- 235000001014 amino acid Nutrition 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000010166 immunofluorescence Methods 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 241000282695 Saimiri Species 0.000 description 4
- 101000980867 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Curved DNA-binding protein Proteins 0.000 description 4
- 101000982319 Shallot virus X Uncharacterized ORF4 protein Proteins 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 229960000789 guanidine hydrochloride Drugs 0.000 description 4
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 4
- 239000012133 immunoprecipitate Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 108010022999 Serine Proteases Proteins 0.000 description 3
- 102000012479 Serine Proteases Human genes 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- XSYUPRQVAHJETO-WPMUBMLPSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-imidaz Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CN=CN1 XSYUPRQVAHJETO-WPMUBMLPSA-N 0.000 description 2
- 101710157236 41 kDa protein Proteins 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 101000829189 Staphylococcus aureus Glutamyl endopeptidase Proteins 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 108010052305 exodeoxyribonuclease III Proteins 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000003936 merozoite Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000003463 organelle Anatomy 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 210000001563 schizont Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- CJDRUOGAGYHKKD-XMTJACRCSA-N (+)-Ajmaline Natural products O[C@H]1[C@@H](CC)[C@@H]2[C@@H]3[C@H](O)[C@@]45[C@@H](N(C)c6c4cccc6)[C@@H](N1[C@H]3C5)C2 CJDRUOGAGYHKKD-XMTJACRCSA-N 0.000 description 1
- 101150028074 2 gene Proteins 0.000 description 1
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100086436 Caenorhabditis elegans rap-1 gene Proteins 0.000 description 1
- 101100119854 Candida albicans FCR3 gene Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 101100420081 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) rps-0 gene Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241001044169 Parum Species 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 241000224017 Plasmodium berghei Species 0.000 description 1
- 241000223830 Plasmodium yoelii Species 0.000 description 1
- 101150015730 Prlr gene Proteins 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 101100115246 Rattus norvegicus Cx3cr1 gene Proteins 0.000 description 1
- 241001620634 Roger Species 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 108020005038 Terminator Codon Proteins 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000011544 gradient gel Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 229940124735 malaria vaccine Drugs 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 238000012510 peptide mapping method Methods 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003355 serines Chemical class 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000003046 sporozoite Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 239000007195 tryptone soya broth Substances 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/20—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans from protozoa
- C07K16/205—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
Definitions
- This invention relates to the cloning of the gene encoding a rhoptry associated protein of Plasmodlum falclpar ⁇ , to the recombinant polypeptide produced by expression of this gene in a host cell, and to the use of this recombinant polypeptide in a vaccine against the malaria parasite.
- the stage of the parasite which invades erythrocytes is the merozoite.
- the rhoptries that are involved in the invasion process.
- the contents of the rhoptries are discharged through ducts and may play an initial role in the formation of the developing parasitophorous vacuole.
- Antigens in the rhoptry contents were amongst the first components identified as potential vaccine candidates. Freeman et.al. (1980) showed that a monoclonal antibody against a protein found in the rhoptries of the rodent malaria Plasmodl ⁇ m yoelll was able to confer passive protection in mice challenged by an otherwise lethal strain of P. yoelll. The target of this monoclonal antibody was purified and shown to induce active protection upon immunization (Holder and Freeman, 1981).
- the rhoptries of the human malarial parasite P. falciparizim have been intensively studied and many proteins have been found which are associated with the rhoptries or associated apical organelles. These include: a 225 kDa antigen (Roger et. al .
- the reported sizes of the components of the 80/42 kDa complex have varied from 80 to 82 kDa and 40 to 42 kDa.
- QF3 The reported sizes of the components of the 80/42 kDa complex
- the complex will be referred to as QF3 but following the nomenclature of Ridley et. al. (1990a), the 80 kDa component will be referred to as RAP-1 (Rhoptry Associated Protein 1) and the 42 kDa component as RAP-2 (Rhoptry Associated Protein 2).
- RAP-2 is not the P.falc ⁇ parinn aldolase (Certa et.al., 1988), not a serine protease (Braun-Breton et.al., 1988) nor related to RAP-1 (Perrin and Dayal, 1982; Ridley et . al . , 1990a) as has been suggested.
- the protein shows a number of unusual characteristics for proteins identified as malarial antigens. It is a basic protein with no repetitive elements and shows minimal sequence diversity in a number of isolates.
- the present invention also extends to a recombinant DNA cloning vector containing a recombinant DNA molecule as broadly described above, as well as to a host cell containing such a recombinant DNA molecule or recombinant DNA cloning vector.
- this invention further extends to a synthetic or recombinant polypeptide displaying the antigenicity of all or a portion of the 42 kDa rhoptry- associated protein of P. falciparum, as well as to compositions for stimulating an immune response against the 42 kDa rhoptry-associated protein of P. falc ⁇ parum which comprise the recombinant polypeptide as described above.
- the recombinant polypeptide is of course produced by expression in a host cell as described above. There is considerable confusion in the literature as to the identity of the P. falciparum RAP-1 and RAP-2 proteins and to their relationship.
- RAP-1 protein is almost always isolated as a series of related bands which have apparently been produced by proteolysis of the parent molecule (Perrin et al., 1985, Schofield et al., 1986, Clark et al., 1987, Bushell et al., 1988, Ridley et al., 1990a).
- RAP-2 may also be a cleavage product of RAP-1.
- Ridley et al., (1990a) found that purified RAP-1 decomposed to give rise to a protein of approximately the same size as RAP-2, reinforcing this view.
- RAP-1 and RAP-2 proteins are closely associated in non-ionic detergent extracts of parasites, antibodies directed against RAP-1 or RAP-2 immunoprecipitate both proteins.
- antibodies only react with RAP-1 or RAP-2 by Western Blotting (Bushell et al., 1988) or immunoprecipitate only RAP-1 or RAP-2 from SDS dissociated proteins (Clark et al., 1987), showing that the two are antigenically distinct.
- Bushell et al., (1988) presented data from peptide mapping to show that RAP-1 and its proteolytic cleavage products were unrelated to RAP-2.
- RAP-1 and RAP-2 are different proteins coded by separate genes. Comparison of the sequences show that these proteins are quite different: no significant homology exists between the DNA or protein sequences.
- RAP-2 is considerably more basic than RAP-1. However, both have a number of moderately hydrophobic domains which probably accounts for the difficulty in keeping purified RAP-1, RAP-2 and their complex, QF3, in solution in the absence of detergents such as SDS (data not shown) and for the association of QF3 with membranous material apparently discharged from rhoptries (Bushell et al., 1988). No significant homology was found between the RAP-2 protein and any protein sequence in the NBRF data bank, or by comparing the RAP-2 protein sequence with the nucleic acid sequences in the GENBANK data base, translated in all 6 reading frames.
- the RAP-2 used herein was derived from the QF3 complex. This was itself purified by immunoaffinity chromatography on monoclonal antibody 7H8/50 directed against RAP-1. An amino acid sequence determined from a V8 protease fragment of the RAP-1 protein isolated during this procedure is contained within the RAP-1 sequence determined by Ridley et al., (1990a). This conclusively demonstrates that the RAP-2 protein described in this paper and the RAP-1 protein described by Ridley et al., (1990a) are the two components of the QF3 complex. This is important since several other proteins with sizes approximating RAP-1 and RAP-2 have been described in the rhoptries.
- RAP-1 and the 76 kDa protease are not the same protein.
- the 41 kDa doublet immunoprecipitated with the protease by 31 cl3 could be RAP-2.
- RAP-2 is clearly associated with RAP-1 in the QF3 complex, the data do not rule out the possibility that it may associate with other proteins.
- an alternative explanation is more likely.
- 31 cl3 has been reported as binding to the P. falciparum aldolase (Certa et al,, 1988) which also has a size of 41 kDa.
- RAP-2 is not aldolase.
- the parasite aldolase shows no significant homology to RAP-2, the possibility still remains that they may share, by chance, a common epitope.
- Cross reactivity has been frequently observed with other malarial proteins (Saul et al., 1989) and there are several tripeptides shared by both sequences which could form the basis of shared epitopes.
- RAP-2 protein is important in interpreting the published vaccine studies in Saimiri monkeys.
- Perrin et al., (1985) used a mixture of proteins purified on monoclonal antibodies 28 ell directed against aldolase, 31 cl3 directed against both the 82 kDa protease and aldolase and 50 ell which immunoprecipitates an 82/41 kDa doublet located in the rhoptries which may be QF3.
- One group of monkeys received the mixture of all the proteins recognized by these monoclonal antibodies.
- a second group received a mixture of just the 41 kDa proteins. Both groups of monkeys showed significant protection but the group receiving the total mixture had lower peak parasitaemias.
- a major component in the 41 kDa mixture was aldolase. Although monoclonal antibody 28 cl2 inhibited parasite growth in vitro (Perrin et al., 1981), in subsequent experiments, recombinant aldolase was ineffective in inducing protective immunity in Saimiri monkeys (Herrera et al., 1990). Therefore it is likely that RAP-2 was the effective component of the 41 kDa mixture.
- Figure 1 shows the restriction map and cloning strategy of the RAP-2 gene. Restriction sites shown are those confirmed experimentally. Bars represent the area encoded in each clone with thick line indicating the region sequenced. RAP-2/3,4,5 were generated from inverted PCR and the clones contain discontinuous regions. The splice site in these clones is indicated by the dotted line.
- Figure 2 shows expression of recombinant RAP-2.
- Transformed bacterial cells were grown in tryptone soya broth to an A 550 of 9.8 to 1.0 and induced with 2 mM ⁇ - isopropylthiogalactoside as described by St ⁇ ber et.al. , (1990). After boiling in the presence of 5% ⁇ -mercapto- ethanol, SDS solubilized protein from extracts of D10 schizonts or from induced bacterial cells transfected with the RAP-2 recombinant or expression plasmid alone were separated by SDS PAGE on 12% polyacrylamide gels. Gels were either (A) stained with Coomassie blue or (B) transferred to nitrocellulose and probed with MAb 3A9/48 as previously described (Bushell et. al . , 1988). Position of the RAP-2 is indicated: on this 12% gel system, RAP-2 has an apparent size of 35 kDa, previous estimates of approximately 40 kDa were based on 7.5% polyacrylamide gels.
- Figure 3 shows: (A) the nucleotide and deduced amino acid sequence of the RAP-2 clone.
- Figure 4 shows the hydrophobicity profile of the RAP-2 protein.
- P. falciparum lines were grown in vitro in human red cells and 10% serum (Trager and Jensen, 1975). The following lines were used for immunofluorescence studies: D10 clone of FCQ-27/PNG (Anders et al., 1983); clone 3D7 of NF54, clone HB3 of HI, clone XCLIO from a cross of 3D7 and HB3 (Walliker et al .,1987); Palo Alto (Chang et al., 1988), Malayan Camp (Leech et al., 1984); Indochina 1 and FVO (Stanley et al., 1985); clone ITG2 (Mattel et al., 1988); FCR3 (Hadley et al., 1983); Wellcome-Liverpool (Holder & Freeman, 1982); clone 7G8 (Burkot et al., 1984), Kl (Thaitong &
- 3E4/64 and 3H7/64 were obtained from mice immunized with affinity purified QF3 crosslinked to bovine serum albumin with glutaraldehyde, the other MAbs were from mice immunized with glutaraldehyde fixed schizonts of the FCQ-27/PNG isolate.
- 3A9/48, 3D9/50, 3E6/64 and 3H7/64 recognize RAP-2.
- 3A9/48 and 3D9/50 recognized the antigen on reduced blots. 7H8/50 recognizes RAP-1. Immunofluorescence assays were done on thin films of parasites, fixed for 10 min in acetone/methanol (90:10 v/v) at -20°C as previously described (Bushell et al., 1988).
- QF3 was purified by immunoaffinity chromatography using 7H8/50 and preparative electrophoresis then cleaved with Staphylococcus aureus V8 protease as previously described (Bushell et al., 1989). Intact QF3 complex or the individual V8 cleaved peptides were electrophoresed using the discontinuous SDS polyacrylamide system of Moos et al., (1988). Following electrophoresis, the proteins were electrophoretically transferred to a polyvinyl difluoride membrane, stained with 0.1% coomassie blue R250 in 50% methanol for 5 min, destained for 10 min in 50% methanol and washed with water. The stained bands were excised then sequenced in an Applied Biosystems model 470 sequencer.
- the polymerase chain reaction used to amplify RAP- 2 gene fragments used the Perkin Elmer Cetus Gene Amp kit according to the manufacturers instructions.
- Forward primer [PR1F: cgaattcAAATT(A/G)TA(T/C)CCNGA, (lower case indicates added restriction sites)] and reverse primer [PRlR:gcaagctt(A/T)GC(A/T)GT(A/G)TGNGC(A/G)TA] were synthesised using a model 381 oligonucleotide synthesiser (Applied Biosystems) and used to amplify a 69 bp fragment (54 bp of malaria sequence and 15 bp of linker).
- the DNA was electrophoresed on a 4% NuSieve agarose (FMC BioProducts, Me., USA), and the band corresponding to the expected size was excised, reamplified and cloned into M13mpl8. It was sequenced using the dideoxy chain termination method with [ 35 S]dATP and Klenow polymerase using standard techniques. This clone was used to probe Southern blots of digested DNA to produce a restriction map. On this map, the cloned sequence was contained within a 1.2kb Dra I fragment.
- the sequence from the RAP2/1.1 clone to the 3' end of this Dra I fragment was amplified by ligating annealed double strand synthetic oligomer GTAAAACGACGGCCAGT (the M13 universal primer sequence) to Dra I restricted D10 DNA; size fractionating the ligated DNA on 1% agarose gel to remove excess oligomer, then amplifying this DNA in a PCR with Ml3 sequencing primer and a primer derived from the unique sequence in RAP- 2/1.1, PR2F: gggaattcAAATTCTTTGACTGGTT.
- Dra I fragment was sequenced into M13mpl8 and sequenced following amplification in an inverted PCR (Triglia et al., 1989) using DNA cut with Dra I, ligated, then cut with Ssp I; and primers PR3R: gggaattcAACATGTGCAGTGTG and PR3F: gggaattcCAGAAAACTTCAAAGC from the 5' and 3' regions of RAP2/2.1 respectively.
- Southern blots of chromosomes were prepared as previously described (Limbaiboon et al., 1991). Briefly, agarose embedded blocks of D10, 3D7 and HB3 were prepared, Iysed, and the chromosomes separated by pulse field gradient gel electrophoresis in 1% agarose with a pulse time of 150- 270 sec (ramping) at 100V for 24 h, 270 sees at 100 V for 20 h and finally 999 sec at 60 V for 52 h. The DNA was transferred to Hybond-N membranes (Amersham) then probed with labelled insert from RAP2/2.1.
- Chromosomes are numbered according the decreasing mobility of the 3D7 clone and the identity of chromosomes in other isolates confirmed with a panel of chromosome specific probes. Chromosome 5 on which the RAP-2 gene was located, hybridized to a probe containing part of the MESA gene (Coppel et al., 1986).
- DNA from D10, HB3, 3D7 and Palo Alto was amplified using primers catcacggatccAAAAAAGAGCAACAAAATGGG and ctctagagtcgacTTAAAGAACAATTAATTCTC corresponding to the N and C termini of the full length protein.
- the DNA was cut with Bam HI and Sal I and cloned into Bam HI/Sal I cut M13mpl8 and M13mpl9. Several clones from each parasite line were sequenced to give the 5' and 3' ends of the corresponding genes.
- the amplified DNA was digested with Rsa I and cloned into M13mpl8. Several clones covering both orientations from each isolate were sequenced.
- DNA from D10 and 3D7 was amplified using primers catcacggatccGATAAGTGTGAAACTG corresponding to the N terminus of the mature protein and the C terminal primer used above.
- Appropriately digested PCR amplification products were ligated into the Bam HI /Sal I site of the hexaHis expression vector pDS56/RBSII,6XHIS (St ⁇ ber et. al . , 1990) and the resulting recombinants were subsequently transformed into E. coli SG13009 (Gottesmann et.al., 1981). The host strain had been transformed previously with the lacl-bearing plasmid, pUHAl.
- the transformed bacterial cells were grown as described previously and the recombinant protein was expressed as an insoluble inclusion body. It was substantially- purified (> 80% pure) by dissolving the cells in 6M guanidine hydrochloride, 0.1M sodium phosphate, pH 8.0, followed by affinity chromatography on a nickel chelate column (St ⁇ ber et.al., 1990).
- the recombinant protein eluted in a pH 4.5 buffer containing 6M guanidine hydrochloride, or a pH 4.9 buffer containing 8 M urea.
- a higher purity could be obtained by first purifying the inclusion bodies, as follows.
- Bacterial cells were resuspended in 24% sucrose, a 0.75M guanidine hydrochloride, 0.1 M sodium phosphate, pH 7.5, and homogenised at 7000 psi with 6 passes through a Martin- Gaulin press. The homogenate was then centrifuged at 7000 psi with 6 passes through a Martin- Gaulin press. The homogenate was then centrifuged at
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP91913838A EP0541629B1 (en) | 1990-08-02 | 1991-08-01 | Cloning and expression of a rhoptry associated protein of (p.falciparum) |
DE69130675T DE69130675T2 (en) | 1990-08-02 | 1991-08-01 | CLONING AND EXPRESSION OF A RHOPTRY-ASSOCIATED PROTEIN FROM P. FALCIPARUM |
US07/971,759 US5573943A (en) | 1990-08-02 | 1991-08-01 | Cloning and expression of a rhoptry associated protein of P. falciparum |
CA002088478A CA2088478C (en) | 1990-08-02 | 1991-08-01 | Cloning and expression of a rhoptry associated protein of p. falciparum |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPK152590 | 1990-08-02 | ||
AUPK1525 | 1990-08-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1992002623A1 true WO1992002623A1 (en) | 1992-02-20 |
Family
ID=3774860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU1991/000338 WO1992002623A1 (en) | 1990-08-02 | 1991-08-01 | CLONING AND EXPRESSION OF A RHOPTRY ASSOCIATED PROTEIN OF $i(P.FALCIPARUM) |
Country Status (10)
Country | Link |
---|---|
US (1) | US5573943A (en) |
EP (1) | EP0541629B1 (en) |
JP (1) | JPH05508996A (en) |
AT (1) | ATE174963T1 (en) |
CA (1) | CA2088478C (en) |
DE (1) | DE69130675T2 (en) |
IL (1) | IL99034A (en) |
MY (1) | MY107451A (en) |
WO (1) | WO1992002623A1 (en) |
ZA (1) | ZA916106B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1284995A2 (en) * | 2000-05-31 | 2003-02-26 | Institut Pasteur | Proteins involved in cytoadhesion of plasmodium falciparum ring-stage-infected erythrocytes |
US20040013671A1 (en) * | 2000-05-31 | 2004-01-22 | Institut Pasteur | Antibodies which bind to proteins involved in cyttoadhesion of Plasmodlum falciparum ring-stage-infected erythrocytes |
US20040082048A1 (en) * | 2002-10-15 | 2004-04-29 | Viswanath Nittala Venkata Narasimha | Genes and protein sequences useful as drug targets for therapeutic action against protozoa |
WO2008055254A2 (en) * | 2006-11-01 | 2008-05-08 | Board Of Regents, The University Of Texas System | Formulations and methods for oral delivery of proteins |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0252098A4 (en) * | 1985-12-24 | 1989-11-29 | Inst Medical W & E Hall | ASEXUAL BLOOD STAGE ANTIGENS OF -i(PLASMODIUM FALCIPARUM). |
ZA888983B (en) * | 1987-12-01 | 1989-08-30 | Saramane Pty Ltd | Rhoptry antigen of plasmodium falciparum |
-
1991
- 1991-08-01 EP EP91913838A patent/EP0541629B1/en not_active Expired - Lifetime
- 1991-08-01 JP JP3512707A patent/JPH05508996A/en active Pending
- 1991-08-01 IL IL9903491A patent/IL99034A/en not_active IP Right Cessation
- 1991-08-01 AT AT91913838T patent/ATE174963T1/en not_active IP Right Cessation
- 1991-08-01 CA CA002088478A patent/CA2088478C/en not_active Expired - Lifetime
- 1991-08-01 WO PCT/AU1991/000338 patent/WO1992002623A1/en active IP Right Grant
- 1991-08-01 DE DE69130675T patent/DE69130675T2/en not_active Expired - Lifetime
- 1991-08-01 MY MYPI91001393A patent/MY107451A/en unknown
- 1991-08-01 US US07/971,759 patent/US5573943A/en not_active Expired - Lifetime
- 1991-08-02 ZA ZA916106A patent/ZA916106B/en unknown
Non-Patent Citations (4)
Title |
---|
Mol. Biochem. Parasitol.; (1987) Vol. 25(1) pages 73-81, "A CDNA clone expressing a rhoptry protein of Plasmodium falciparum". * |
Mol. Biochem. Parasitol.; (1988) Vol. 18(2) pages 183-95, "A Rhoptry antigen of Plasmodium Falciparum contains conserved and variable epitopes recognized by inhibitory monoclonal antibodies". * |
Mol. Biochem. Parasitol.; (1988) Vol. 28(2), pages 105-12, "An antigenic complex in the rhoptries of Plasmodium falciparum". * |
Mol. Biochem. Parasitol.; (1990) Vol. 41(1) pages 125-34, "Characterization and sequence of a protective rhoptry antigen from plasmodium falciparum". * |
Also Published As
Publication number | Publication date |
---|---|
EP0541629A4 (en) | 1993-12-29 |
IL99034A (en) | 1996-10-16 |
JPH05508996A (en) | 1993-12-16 |
EP0541629B1 (en) | 1998-12-23 |
US5573943A (en) | 1996-11-12 |
DE69130675T2 (en) | 1999-10-14 |
DE69130675D1 (en) | 1999-02-04 |
CA2088478C (en) | 2002-06-11 |
MY107451A (en) | 1995-12-31 |
ATE174963T1 (en) | 1999-01-15 |
ZA916106B (en) | 1992-06-24 |
CA2088478A1 (en) | 1992-02-03 |
EP0541629A1 (en) | 1993-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ridley et al. | Characterisation and sequence of a protective rhoptry antigen from Plasmodium falciparum | |
Ridley et al. | A rhoptry antigen of Plasmodium falciparum is protective in Saimiri monkeys | |
Saul et al. | The 42-kilodalton rhoptry-associated protein of Plasmodium falciparum | |
Etlinger et al. | Ability of recombinant or native proteins to protect monkeys against heterologous challenge with Plasmodium falciparum | |
EP0154454B1 (en) | Cloning of dna for protozoal antigens | |
AU694142B2 (en) | Binding domains from plasmodium vivax and plasmodium falciparum erythrocyte binding proteins | |
Knapp et al. | Protection of Aotus monkeys from malaria infection by immunization with recombinant hybrid proteins | |
WO1997026911A1 (en) | Malaria vaccine based upon the addition of a msa1 peptide | |
AU584881B2 (en) | Improvements in or relating to the production of malaria vaccines | |
EP0541629B1 (en) | Cloning and expression of a rhoptry associated protein of (p.falciparum) | |
US5116755A (en) | Asexual blood stage antigens of plasmodium falciparum which encode a rhoptry protein | |
AU645831B2 (en) | Cloning and expression of a rhoptry associated protein of P.falciparum | |
Barnes et al. | Plasmodium falciparum: D260, an intraerythrocytic parasite protein, is a member of the glutamic acid dipeptide-repeat family of proteins | |
US5238836A (en) | Plasmodium falciparum merozoite antigen peptides | |
US5393523A (en) | Plasmodium falciparum vaccine comprising a recombinant histidine-rich protein-HRP-II | |
WO1995008631A2 (en) | Target antigens of transmission blocking antibodies for malaria parasites | |
SAUL et al. | Sommaire du brevet 2088478 | |
IE80429B1 (en) | Protective plasmodium falciparum hybrid proteins which contain partial sequences of the malaria antigens HRPII and SERP | |
EP0433378B1 (en) | ALLELIC VARIANTS OF $i(PLASMODIUM FALCIPARUM) MEROZOITE SURFACE ANTIGEN | |
WO1992001705A1 (en) | Plasmodium vivax and plasmodium knowlesi duffy receptor | |
IE910966A1 (en) | Plasmodium Sporozoite Antigen | |
WO1989007645A1 (en) | Rhoptry membrane antigen of plasmodium falciparum | |
AU638216C (en) | Allelic variants of plasmodium falciparum merozoite surface antigen | |
EP0388738B1 (en) | Plasmodium merozoite rhoptries antigen and derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1991913838 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2088478 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1991913838 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1991913838 Country of ref document: EP |